Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432578 | 0.85 | MAPT (0.58) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15954532 | 0.85 | MAPT (0.56) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30113078 | 0.84 | MAPT (0.58) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29153613 | 0.84 | MAPT (0.58) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15954728 | 0.82 | MAPT (0.55) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15954408 | 0.81 | MAPT (0.53) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28784232 | 0.81 | MAPT (0.56) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2177712 | 0.81 | MAPT (0.68) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29241859 | 0.81 | MAPT (0.68) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6799629 | 0.80 | MAPT (0.56) | NPC1MAPTRAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2958915-A1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2014128585-A1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-8648075-B2 | Substituted pyrido[2,3-b]pyrazines and an agrochemical composition thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130137577-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-8389523-B2 | Substituted quinoxaline and an agrochemical composition thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| EP-2174934-B1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2174934-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137577-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | CBR3, CBR1, DDT | NPC1 4460/4885MAPT 4727/4885RAB9A 1771/4885 |
| US-20150322065-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | NPC1 592/4885MAPT 4007/4885RAB9A 1151/4885 |
| US-20140235612-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | NPC1 592/4885MAPT 4007/4885RAB9A 1151/4885 |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | CBR3, CBR1, DDT | NPC1 4460/4885MAPT 4727/4885RAB9A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.